Patents by Inventor Guy A. Rouleau

Guy A. Rouleau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Short GCG expansions in the PAB II gene for oculopharyngeal muscular dystrophy and diagnostic thereof
    Patent number: 6828430
    Abstract: The present invention relates to a human PAB II gene containing transcribed polymorphic GCG repeat, which comprises a sequence as set forth in SEQ ID NO:18, which includes introns and flanking genomic sequence. Allelic variants of GCG repeat of the human PAB II gene are associated with a disease related with protein accumulation in the nucleus, such as polyalanine accumulation, or with swallowing difficulties, such as oculopharyngeal muscular dystrophy. The present invention also relates to a method for the diagnosis of a disease associated with protein accumulation in the nucleus, which comprises the steps of: a) obtaining a nucleic acid sample of a patient; and b) determining allelic variants of GCG repeat of the PAB II gene, and wherein long allelic variants are indicative of a disease related with protein accumulation in the nucleus.
    Type: Grant
    Filed: June 8, 2000
    Date of Patent: December 7, 2004
    Assignee: McGill University
    Inventors: Guy A. Rouleau, Bernard Brais
  • Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
    Publication number: 20040214195
    Abstract: The present invention relates to epilepsy. More particularly, the present invention relates to idiopathic generalized epilepsy (IGE) and to the identification of three genes mapping to chromosome 2, which show mutations in patients with epilepsy. The invention further relates to nucleic acid sequences, and protein sequences of these loci (SCNA) and to the use thereof to assess, diagnose, prognose or treat epilepsy, to predict an epileptic individual's response to medication and to identify agents which modulate the function of the SCNA. The invention also provides screening assays using SCN1A, SCN2A and/or SCN3A which can identify compounds which have therapeutic benefit for epilepsy and related neurological disorders.
    Type: Application
    Filed: September 17, 2003
    Publication date: October 28, 2004
    Inventors: Guy A. Rouleau, Ronald G. Lafreniere, Daniel Rochefort
  • Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
    Publication number: 20040096885
    Abstract: The present invention relates to epilepsy. More particularly, the present invention relates to idiopathic generalized epilepsy (IGE) and to the identification of three genes mapping to chromosome 2, which show mutations in patients with epilepsy. The invention further relates to nucleic acid sequences, and protein sequences of these loci (SCNA) and to the use thereof to assess, diagnose, prognose or treat epilepsy, to predict an epileptic individual's response to medication and to identify agents which modulate the function of the SCNA. The invention also provides screening assays using SCN1A, SCN2A and/or SCN3A which can identify compounds which have therapeutic benefit for epilepsy and related neurological disorders.
    Type: Application
    Filed: September 17, 2003
    Publication date: May 20, 2004
    Inventors: Guy A. Rouleau, Ronald G. Lafreniere, Daniel Rochefort
  • Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
    Publication number: 20040096886
    Abstract: The present invention relates to epilepsy. More particularly, the present invention relates to idiopathic generalized epilepsy (IGE) and to the identification of three genes mapping to chromosome 2, which show mutations in patients with epilepsy. The invention further relates to nucleic acid sequences, and protein sequences of these loci (SCNA) and to the use thereof to assess, diagnose, prognose or treat epilepsy, to predict an epileptic individual's response to medication and to identify agents which modulate the function of the SCNA. The invention also provides screening assays using SCN1A, SCN2A and/or SCN3A which can identify compounds which have therapeutic benefit for epilepsy and related neurological disorders.
    Type: Application
    Filed: September 17, 2003
    Publication date: May 20, 2004
    Inventors: Guy A. Rouleau, Ronald G. Lafreniere, Daniel Rochefort